# Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL

> **NCT07692399** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Huashan Hospital** · enrollment: 60 (estimated)

## Conditions studied

- CADASIL

## Interventions

- **DRUG:** Edaravone Dexborneol Sublingual Tablets

## Key facts

- **NCT ID:** NCT07692399
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07692399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07692399, "Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07692399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*